Belgian Residential REITs Stock News

Lotus Bakeries (ENXTBR:LOTB) has wrapped up FY 2025 with second half revenue of €697.7 million, basic EPS of €114.31 and net income of €92.9 million, while trailing twelve month revenue sits at about €1.4 billion with EPS of €212.06. The company has seen revenue move from €632.7 million in the second half of 2024 to €657.3 million in the first half of 2025 and €697.7 million in the second half of 2025. EPS over the same periods stepped from €99.12 to €97.74 and then €114.31, setting up a...

Key Insights Significant control over Groupe Bruxelles Lambert by private companies implies that the general public has...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Umicore fair value estimate is €29.83 Umicore's €19.68 share...

It's been a sad week for Melexis NV ( EBR:MELE ), who've watched their investment drop 16% to €53.25 in the week since...

If you are wondering whether SCR-Sibelco is attractively priced right now, this article walks through how its current share price stacks up against a few different valuation checks. The stock last closed at €4,700.00, with returns of a 2.1% decline over 7 days, a 13.8% decline over 30 days, a 13.8% decline year to date and a 6.0% decline over the past year, which may have some investors reassessing both risk and opportunity around the shares. Recent moves in the share price sit against a...

Warehouses De Pauw (ENXTBR:WDP) has drawn fresh attention after reporting full year 2025 results, with gross rents and EBIT slightly ahead of expectations and additional support coming from recent analyst commentary. See our latest analysis for Warehouses De Pauw. The earnings release and recent commentary appear to sit alongside a period of renewed momentum, with a 30 day share price return of 5.86% and 90 day share price return of 11.22%, while the 1 year total shareholder return of 27.16%...

Orange Belgium (ENXTBR:OBEL) FY 2025 Earnings Snapshot Orange Belgium (ENXTBR:OBEL) has just reported its FY 2025 numbers with first half revenue of €962.7 million and basic EPS of €0.04, alongside trailing 12 month revenue of €1.96 billion and EPS of €0.61 that frame the latest run rate. The company recorded revenue of €977.5 million in the first half of 2024 and €1,016.2 million in the second half of 2024, while EPS moved from a loss of €0.20 to a profit of €0.56, before landing at €0.04 in...

Why Lotus Bakeries Stock Is in Focus After Its 2025 Results Lotus Bakeries (ENXTBR:LOTB) is back on investors' radar after reporting full year 2025 earnings, including higher sales, net income and earnings per share, helped by its Natural Foods division and new capacity in Thailand. See our latest analysis for Lotus Bakeries. Investors have responded to the 2025 results and the Thailand and India growth plans with a 21.10% 1 month share price return and a 39.87% 3 month share price return,...

Melexis NV ( EBR:MELE ) has announced that it will pay a dividend of €1.68 per share on the 21st of May. This makes the...

Argenx's Vyvgart is significantly outperforming expectations, with recent sales figures pointing to stronger than anticipated demand. The company is preparing for major Phase 3 trial readouts that are expected to clarify the potential of its broader pipeline. These developments are drawing attention from healthcare investors who view Vyvgart as an important contributor to fund performance. argenx (ENXTBR:ARGX) is drawing fresh interest as Vyvgart's performance adds weight to its current...

If you are trying to work out whether Syensqo is attractively priced or not, the recent share moves and valuation checks give you a useful starting point. Syensqo shares last closed at €78.08, with returns of 10.5% over the past 7 days, 7.1% over 30 days, 11.7% year to date and a 2.2% decline over the past year. This may point to shifting views on both upside potential and risk. Recent news coverage around Syensqo has focused on the company as a standalone listed business. This has kept...

Event context and recent return profile SCR-Sibelco (ENXTBR:094426466) has come onto investors’ radar after recent share price moves, with the stock flat over the past day, weaker over the past month, yet slightly higher across the past 3 months. This mixed return profile, alongside an intrinsic discount indicator of 11.43%, is prompting closer attention to how the company’s €2,299.814m revenue and €63.378m net income relate to current market expectations. See our latest analysis for...

Key Insights Banqup Group's significant individual investors ownership suggests that the key decisions are influenced...

Despite an already strong run, DEME Group NV ( EBR:DEME ) shares have been powering on, with a gain of 26% in the last...

Xior Student Housing (ENXTBR:XIOR) is back in focus after its 2025 earnings call, where management highlighted 5.43% like for like rental growth, 98% occupancy, and set fresh EPS growth guidance alongside new unit expansion plans. See our latest analysis for Xior Student Housing. At a share price of €28.55, Xior Student Housing has seen muted short term share price moves despite the stronger rental growth story. The 1 year total shareholder return of 3.66% decline and 5 year total shareholder...

Melexis (ENXTBR:MELE) has wrapped up FY 2025 with fourth quarter revenue of €214.5 million and basic EPS of €0.56, setting the tone for how investors might judge the year as a whole. Over recent quarters the company has seen revenue move from €197.4 million and EPS of €0.45 in Q4 2024 to a peak of €215.3 million and EPS of €0.94 in Q2 2025, before landing at the latest Q4 figures. This puts the spotlight firmly on how sustainably Melexis can support its earnings power and protect margins from...

Corona Cero, Anheuser-Busch InBev’s non-alcoholic brand, previously unveiled its TIME CERO initiative with the IOC and Athlete365, featuring a global roster of Olympian ambassadors to promote balance and mindfulness during the Olympic Winter Games. This collaboration places Corona Cero at the intersection of sports, wellness, and premium branding, potentially deepening consumer engagement with non-alcoholic offerings worldwide. We’ll now examine how Corona Cero’s Olympic-focused TIME CERO...

argenx (ENXTBR:ARGX) is back in focus after the FDA accepted priority review for an expanded Vyvgart application, alongside fresh analyst commentary pointing to strong Vyvgart sales momentum and higher long term revenue assumptions. See our latest analysis for argenx. At a share price of €717.6, argenx has seen a 4.97% 1 month share price return. Its 1 year total shareholder return of 11.92% and 3 year total shareholder return of 104.04% point to momentum that has built over a longer period,...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...

UCB has received European Union approval for Kygevi to treat thymidine kinase 2 deficiency (TK2d) in patients whose disease began before age 12, marking the first EU-authorized therapy for this rare genetic condition. The decision builds on prior FDA approval and retrospective data showing a very large reduction in risk of death versus untreated TK2d patients, underscoring Kygevi’s medical significance for a small but highly underserved population. We’ll now examine how Kygevi’s first-in-EU...

Warehouses De Pauw SA has released its full-year 2025 results, reporting sales of €451.76 million versus €398.18 million in 2024, while net income moved to €353.92 million from €435.5 million and basic earnings per share from continuing operations shifted to €1.54 from €1.96. This combination of higher revenue but lower profitability in 2025 raises questions about cost trends, portfolio mix, and how the logistics real estate group is managing its earnings profile. We’ll now examine how the...

In recent days, analysts have reiterated positive views on KBC Group, emphasizing its strong profitability, solid capital ratios, and ongoing dividends and buybacks. What stands out is how KBC’s conservative risk approach and continued investment in digital transformation are being framed as core strengths by the analyst community. We’ll now examine how this renewed focus on KBC’s disciplined capital returns shapes the company’s broader investment narrative. Rare earth metals are the new...

With a price-to-earnings (or "P/E") ratio of 13x Colruyt Group N.V. ( EBR:COLR ) may be sending bullish signals at the...

In January, argenx reported continued momentum for its autoimmune drug VYVGART, as the US FDA accepted a priority review of a supplemental biologics license application to extend its use to adults with acetylcholine receptor antibody‑seronegative generalized myasthenia gravis, while the franchise continued to post strong global sales growth in 2025. This combination of regulatory progress and broader clinical ambitions, spanning indications like immune thrombocytopenia, myositis and...